Mexazolam

Mexazolam

Systematic (IUPAC) name
10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
Clinical data
Trade names	Melex, Sedoxil
AHFS/Drugs.com	International Drug Names
Legal status	US: Schedule IV
Routes of administration	Oral
Pharmacokinetic data
Metabolism	Hepatic (CYP3A4)
Excretion	Renal
Identifiers
CAS Number	31868-18-5
ATC code	none
PubChem	CID: 4177
ChemSpider	4033 Y
UNII	S5969B6237 Y
KEGG	D01316 Y
Synonyms	13-chloro- 2-(2-chlorophenyl)- 5-methyl- 3-oxa- 6,9-diazatricyclo[8.4.0.02,6] tetradeca- 1(10),11,13-trien- 8-one
Chemical data
Formula	C18H16Cl2N2O2
Molecular mass	363.237 g/mol
SMILES Clc1ccccc1C42OCC(N2CC(=O)Nc3c4cc(Cl)cc3)C
InChI InChI=1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23) Y Key:ANUCDXCTICZJRH-UHFFFAOYSA-N Y
(verify)

Mexazolam (marketed under the trade names Melex and Sedoxil) is a drug which is a benzodiazepine derivative. Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance. Mexazolam is metabolised via the CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam, but not the HMG-CoA reductase inhibitor pravastatin.

See also

• Benzodiazepine